

Opinion of the Scientific Panel on Contaminants in Food Chain on a request from the Commission related to fumonisins as undesirable substances in animal feed

Request No. EFSA-Q-2003-040

Adopted on 22 June

SUMMARY

Fumonisin is a distinct group of mycotoxins produced by several field fungi, including *Fusarium verticillioides* and *Fusarium proliferatum*. Fumonisin is occurring particularly in maize and maize-based products. Co-occurrence with other *Fusarium* toxins, such as zearalenone and deoxynivalenol, is regularly observed. Fumonisin B₁ is considered to be the most prevalent and most toxic derivative within the group of fumonisins. It is a prototypic inhibitor of cellular sphingosine (sphinganine) N-acetyltransferase. Inhibition of this enzyme is followed by an accumulation of sphinganine (Sa) and sometimes also sphingosine (So) and a depletion of complex sphingolipids in eukaryotic cells, which in turn results in impairment of cell cycle regulation and cellular differentiation, and in oxidative stress as well as apoptosis and necrosis. Fumonisin B₁ is carcinogenic in rodents, but it is devoid of significant genotoxic activity. *In vivo* rodent experiments suggest that fumonisins are tumour promoters. The increased Sa:So ratio in body fluids and tissues serves as a sensitive biomarker of exposure to fumonisins. Equidae and porcine species are considered to be the most sensitive animal species to fumonisins, developing species-specific clinical syndromes such as equine leukoencephalomalacia and porcine pulmonary oedema. Ruminants and poultry show a low responsiveness to fumonisins. Few data are available on the effects of fumonisins on farmed fish and on minor species, such as rabbits, goats and minks. The available data on animal exposure via feedingstuffs are limited and monitoring of feed materials is needed to improve exposure assessment. Available data on carry-over of fumonisins from animal feeds into edible tissues, including milk and eggs, indicate that transfer is limited, and thus residues in animal tissues contribute insignificantly to total human exposure.

KEY WORDS: fumonisins, animal feeds, toxicity, tissue residues

TABLE OF CONTENTS

SUMMARY	1
TABLE OF CONTENTS	2
BACKGROUND.....	3
1. General background	3
2. Specific Background	4
TERMS OF REFERENCE.....	4
ASSESSMENT	5
1. Introduction.....	5
2. Methods of analysis	7
3. Current legislation.....	8
4. Occurrence of fumonisins in feed materials	9
5. Estimating the intake of fumonisins by farm livestock	10
6. Adverse effects on livestock	11
6.1. Adverse effects in pigs	11
6.2. Adverse effects in poultry	13
6.3. Adverse effects in ruminants.....	15
6.4. Adverse effects in horses	16
6.5. Adverse effects in other animal species	17
6.5.1. Rabbits.....	17
6.5.2. Mink	17
6.5.3. Fish.....	18
6.5.4. Rodents.....	19
7. Toxicokinetics, metabolism and tissue distribution.....	19
8. Carry-over and residues	20
9. Human dietary exposure	21
RECOMMENDATIONS	22
REFERENCES.....	23
SCIENTIFIC PANEL MEMBERS	32
ACKNOWLEDGEMENT	32

BACKGROUND

1. General background

Directive 2002/32/EC of the European Parliament and of the Council of 7 May 2002 on undesirable substances in animal feed¹ replaces since 1 August 2003 Council Directive 1999/29/EC of 22 April 1999 on the undesirable substances and products in animal nutrition².

The main modifications can be summarised as follows:

- extension of the scope of the Directive to include the possibility of establishing maximum limits for undesirable substances in feed additives.
- deletion of the existing possibility to dilute contaminated feed materials instead of decontamination or destruction (introduction of the principle of non-dilution).
- deletion of the possibility for derogation of the maximum limits for particular local reasons.
- introduction the possibility of the establishment of an action threshold triggering an investigation to identify the source of contamination (“early warning system”) and to take measures to reduce or eliminate the contamination (“pro-active approach”).

In particular the introduction of the principle of non-dilution is an important and far-reaching measure. In order to protect public and animal health, it is important that the overall contamination of the food and feed chain is reduced to a level as low as reasonably achievable providing a high level of public health and animal health protection. The deletion of the possibility of dilution is a powerful mean to stimulate all operators throughout the chain to apply the necessary prevention measures to avoid contamination as much as possible. The prohibition of dilution accompanied with the necessary control measures will effectively contribute to safer feed.

During the discussions in view of the adoption of Directive 2002/32/EC the Commission made the commitment to review the provisions laid down in Annex I on the basis of updated scientific risk assessments and taking into account the prohibition of any dilution of contaminated non-complying products intended for animal feed. The Commission has therefore requested the Scientific Committee on Animal Nutrition (SCAN) in March 2001 to provide these updated scientific risk assessments in order to enable the Commission to finalise this review as soon as possible (Question 121 on undesirable substances in feed)³.

The opinion on undesirable substances in feed, adopted by SCAN on 20 February 2003 and updated on 25 April 2003⁴ provides a comprehensive overview on the possible risks for

¹ OJ L140, 30.5.2002, p. 10

² OJ L 115, 4.5.1999, p. 32

³ Summary record of the 135th SCAN Plenary meeting, Brussels, 21-22 March 2001, point 8 – New questions (http://europa.eu.int/comm/food/fs/sc/scan/out61_en.pdf)

⁴ Opinion of the Scientific Committee on Animal Nutrition on Undesirable Substances in Feed, adopted on 20 February 2003, updated on 25 April 2003 (http://europa.eu.int/comm/food/fs/sc/scan/out126_bis_en.pdf)

animal and public health as the consequence of the presence of undesirable substances in animal feed.

It was nevertheless acknowledged by SCAN itself for several undesirable substances and by the Standing Committee on the Food Chain and Animal Health section Animal Nutrition that additional detailed risks assessments are necessary to enable a complete review of the provisions in the Annex, including the establishment of maximum levels for undesirable substances currently not listed.

2. Specific Background

Fumonisin are formed mainly by *Fusarium verticillioides* (syn. *Fusarium moniliforme*) and *Fusarium proliferatum*. At least 12 fumonisin analogues are known, the most important being the B series (fumonisins B₁, B₂ and B₃). The most significant crop, in which fumonisins occur, is maize, particularly when grown in warmer regions.

No maximum levels for fumonisins in animal feed have been established in EU legislation.

Maximum levels for fumonisins in foodstuffs and more in particular for the sum of Fumonisin B₁ and B₂, are currently under discussion at EU level.

SCAN concluded⁵ that fumonisins can be responsible for serious adverse health effects in horses and pigs.

Given the high concentrations of fumonisins that may be found in maize especially in imported from warm regions, the introduction of control measures should be considered. It is therefore appropriate that a full risk assessment should be undertaken.

TERMS OF REFERENCE

The European Commission requests the EFSA to provide a detailed scientific opinion on the presence of fumonisins in animal feed.

This detailed scientific opinion should comprise the

- determination of the toxic exposure levels (daily exposure) of fumonisins for the different animal species of relevance (difference in sensitivity between animal species) above which
 - signs of toxicity can be observed (animal health / impact on animal health) or
 - the level of transfer/carry over of fumonisins from the feed to the products of animal origin results in unacceptable levels of fumonisins in the products of animal origin in view of providing a high level of public health protection.

⁵ Opinion of the Scientific Committee on Animal Nutrition on Undesirable Substances in Feed, point 7.6. Conclusions and recommendations.

- identification of feed materials which could be considered as sources of contamination by fumonisins and the characterisation, insofar as possible, of the distribution of levels of contamination
- assessment of the contribution of the different identified feed materials as sources of contamination by fumonisins
- to the overall exposure of the different relevant animal species to fumonisins,
 - to the impact on animal health
 - to the contamination of food of animal origin (the impact on public health), taking into account dietary variations and carry over rates⁶.
- identification of eventual gaps in the available data which need to be filled in order to complete the evaluation.

ASSESSMENT

1. Introduction

Fumonisins such as B₁, B₂, B₃ and B₄ are mycotoxins produced by various fungi of the genus *Fusarium*, primarily by *Fusarium verticillioides* (formerly named *F. moniliforme*) and the related *F. proliferatum*, although other fungal species including *F. napiforme*, *F. dlamini* and *F. nygamai* are also able to produce fumonisins (US-NTP, 1999; WHO-IPCS, 2000). *F. verticillioides* and *F. proliferatum* are common fungi associated with maize causing ‘Fusarium kernel rot’ an important plant disease in hot climates. ‘Fusarium kernel rot’ may also be induced by *F. graminearum* and a strong relationship exists between insect damage, temperature stress, and fungal invasion, especially in cultivars grown outside their area of adaptation. As *F. verticillioides* and *F. proliferatum* grow over a wide range of temperatures but only at relatively high water activities ($a_w > 0.9$), fumonisins are formed in maize prior to harvest or during the early stage of storage. Except under extreme conditions, the concentrations of fumonisins do not increase during storage.

Fumonisins have been found as natural contaminants in maize and maize-based food from many parts of the world, e.g. the U.S.A., Canada, South Africa, Italy, Poland and Spain (Eriksen and Alexander, 1998; WHO-IPCS, 2000). Many countries have generated data on occurrence of fumonisins in grains (mostly maize) and grain-based foods. A SCOOP report on *Fusarium* toxins has recently become available, which includes data on fumonisins in foodstuffs from 9 European countries (EC, 2003a).

⁶ Importance of the human exposure to fumonisins from foods of animal origin compared to overall human dietary fumonisin exposure can be assessed making use of the information contained in the report on a task on human exposure assessment to fumonisin which has been finalised in July 2003 at EU level within the framework of co-operation by Member States in the scientific examination of questions related to food (SCOOP – Task 3.2.10 – *Fusarium* toxins) (EC, 2003a)

Fumonisin B₁ (FB₁) is the most significant of the fumonisins in terms of toxicity and occurrence. FB₁ is chemically described as 1,2,3-propanetricarboxylic acid, 1,1'-[1-(12-amino-4,9,11-trihydroxy-2-methyltridecyl)-2-(1-methylpentyl)-1,2-ethanediyl]ester (C₃₄H₅₉NO₁₅, MW 721.838, CAS No 116355-83-0). The structure of FB₁ is shown in Figure 1. Fumonisin B₂ (FB₂) is a deoxy analogue of FB₁ in which the corresponding epimeric units on the eicosane backbone have the same configuration. The full stereochemistry of fumonisins B₃ (FB₃) and B₄ is unknown yet, but the amino terminal of FB₃ has the same absolute configuration as that of FB₁ (Bolger *et al.*, 2001; WHO-IPCS, 2000).




Figure 1. Chemical structure of fumonisin B₁.

Maize screenings contain higher concentrations of fumonisins than whole grain. Separation and removal of screenings reduces the levels of fumonisins prior to storage, but the screenings are used in animal feeds. Both, wet and dry milling of maize, results in distribution of fumonisins into various maize fractions with high concentrations predominantly in those fractions destined for animal feed. Fumonisins are fairly heat-stable, and the toxin content is significantly reduced only during processes in which the temperature exceeds 150°C. There is little degradation of fumonisins during fermentation.

A range of toxic syndromes have been associated with exposure to fumonisins including Equine Leukoencephalomalacia (ELEM), Porcine Pulmonary Edema (PPE) and hepatic and renal injury in most species tested. Fumonisin exposure results also in hemodynamic alterations, considered to be involved in the pathogenesis of both, ELEM and PPE.

In resembling the structure of sphingosine, sphinganine and related complex sphingolipids fumonisins inhibit sphingosine (sphinganine) N-acetyltransferase (ceramide synthetase) thus blocking the synthesis of complex sphingolipids (Merrill *et al.*, 1996; Norred *et al.*, 1998; Wang *et al.*, 1999; Yoo *et al.*, 1992). Subsequently, an accumulation of sphinganine (and sometimes also sphingosine) and a depletion of complex sphingolipids has been observed in a variety of cultured cells (Norred *et al.*, 1998; Schroeder *et al.*, 1994; Tolleson *et al.*, 1999), and in sera, liver, kidney and urine of animals fed contaminated grains (Merrill *et al.*, 1997; Riley *et al.*, 1993; Van der Westhuizen *et al.*, 2001; Wang *et al.*, 1992). The increased ratio of sphinganine to sphingosine (Sa:So ratio) is the most sensitive indicator for exposure to fumonisin. The disruption of the sphingolipid metabolism presumably accounts also for the major biological effects exerted by fumonisins including impairment of cell growth and differentiation, cellular oxidative stress, and apoptosis and necrosis (Ciacci-Zanella and Jones, 1999; He *et al.*, 2002; Howard *et al.*, 1995; Norred *et al.*, 1998; Sharma *et al.*, 1997).

In 1993 and 2002 IARC evaluated FB₁ and classified it in Group 2B: "Possible carcinogenic to humans" (IARC, 1993, 2002), as FB₁ has been shown to produce kidney and liver tumours

in rodents (FAO/WHO, 2002, US-NTP, 1999) but there is no adequate evidence that FB₁ is genotoxic. It is assumed that FB₁ acts as tumour promotor (Gelderblom *et al.* 1996). Human exposure to FB₁ has been associated with oesophageal cancer and neural tube effects in humans (for details see EC 2003b).

Risk assessments for fumonisins have been performed by the Scientific Committee on Food (SCF) (EC, 2000, 2003b), the Joint FAO/WHO Expert Committee on Food Additives (JECFA) (FAO/WHO, 2002) and a Nordic Working Group (Eriksen and Alexander, 1998). A group provisional maximum tolerable daily intake (PMTDI) for FB₁, FB₂ and FB₃ of 2µg/kg body weight was established by JECFA. A group tolerable daily intake (TDI) of 2µg/kg body weight was also established by SCF (EC 2003b). The tolerable intake established by JECFA and SCF was based on a NOEL of 0.2 mg FB₁/kg b.w./day for kidney toxicity in the rat, the most sensitive adverse effect observed.

Concerning agriculture animal species and experimental laboratory species the SCF summarised NOAEL levels from diverse studies as follows (Table 1):

Table 1. NOAEL's from diverse studies, expressed as mg FB₁/kg b.w./day

Species	Duration	Target organ /effect	NOAEL (mg/kg b.w.)	Reference
Rat	Short-term	Liver	< 0.75	Gelderblom <i>et al.</i> , 1994
Pig	Short-term	Lung/ PPE	< 4.5	Motelin <i>et al.</i> , 1994
		Lung/heart	0.2	Zamborsky-Kovács <i>et al.</i> , 2002b ⁷
Horse	Short-term	Brain/ ELEM	0.2	Ross <i>et al.</i> , 1994
Mouse	Subchronic	Liver	1.8	Voss <i>et al.</i> , 1995
Rat	Subchronic	Kidney	0.2	Voss <i>et al.</i> , 1995
Rat	Chronic	Liver	1.25	Gelderblom <i>et al.</i> , 1995
Mouse	Chronic	Liver	0.6	US-NTP, 1999
Rat	Chronic	Kidney	0.25	US-NTP, 1999

2. Methods of analysis

For the monitoring of the occurrence of fumonisins in food and feed commodities, mainly chromatographic methods of analysis are used, reviewed by Shephard (1998) and updated by

⁷ This study was not considered by SCF

the same author (FAO/WHO, 2001). There is evidence that some fumonisins are matrix-bound. They may also occur bound to proteins and sugars in the matrix (Humpf and Voss, 2004; Kim *et al.*, 2003; Seefelder *et al.*, 2003). Extraction conditions need to be sufficiently rigorous to ensure good recovery of the unbound and/or hydrolysed toxins (Park *et al.*, 2004; Seefelder *et al.*, 2001). Most methods for fumonisins include solid phase extraction (SPE) or, more often, immunoaffinity (IA) cleanup, followed by pre-column derivatisation with o-phthaldialdehyde as derivatisating agent, and liquid chromatography (LC) separation with fluorescence detection. For screening purposes enzyme-linked immunosorbent assays (ELISA) can be used. Two LC-methods and an ELISA have received AOAC Official Method status (AOAC International, 2000). They were validated for maize and certain maize products. LC followed by mass spectrometric (MS) detection is gaining popularity (Musser *et al.*, 2002) but a formal interlaboratory validation has not been conducted yet. An alternative is the application of reverse-phase thin-layer chromatography (TLC). A collaborative study with maize as test material has shown good performance of this approach for semi-quantitative purposes (Shephard and Sewram, 2004). Formally validated methods for (mixed) feedingstuffs are currently not available.

Certified matrix reference materials are not available for fumonisins. Calibrants of FB₁ and FB₂ are commercially available. The Food Analysis Performance Assessment Scheme (FAPAS[®]) organises proficiency tests for FB₁ and FB₂ twice yearly. Recent FAPAS studies (FAPAS, 2000, 2001a,b, 2002, 2003) indicate that LC-fluorescence is the preferred analytical technique, whereas ELISA, TLC and LC-MS are used to a much lesser extent. The studies showed that “satisfactory Z-scores” for the participants ranged from 44 % to 76 % for FB₁ and from 55 % to 82 % for FB₂ in various maize test materials and one blended maize/wheat test material, with assigned values ranging from 650 µg/kg to 4879 µg/kg for FB₁ and from 306 µg/kg to 2220 µg/kg for FB₂. Further studies are necessary to improve the analytical performance of test laboratories analysing for fumonisins.

3. Current legislation

Whereas in 1995 fumonisins were only subject of regulations in one country (FAO, 1997) this number has now increased to six, with limits for maize ranging from 1000 – 3000 µg/kg (FAO, 2004). In Europe, fumonisins are now regulated in Bulgaria (FB₁ and FB₂ in maize and maize products), in France (FB₁ in cereals and cereal products), and in Switzerland (FB₁ and FB₂ in maize). Specific EU-harmonised limits for fumonisins in food or feed have not been established yet. Limits for FB₁, FB₂ and FB₃ in animal feeds currently only exist in the USA, as guidance levels for industry. Different limits are applied, depending on the destination of the feed, and are specified for equidae, rabbits, swine, catfish, ruminants, poultry, mink and pet animals (Table 2).

Table 2. Industry guidance levels for the sum of fumonisins B₁, B₂ and B₃ in animal feedstuffs as applied in the USA (US-FDA, 2001).

Type of feed	Limit (µg/kg)	Remarks
Corn and corn byproducts intended for equids and rabbits	5000	No more than 20 % of diet on dry weight basis
Corn and corn byproducts intended for swine and catfish	20,000	No more than 50 % of diet on dry weight basis
Corn and corn byproducts intended for breeding ruminants, breeding poultry and breeding mink (includes lactating dairy cattle and hens laying eggs for human consumption)	30,000	No more than 50 % of diet on dry weight basis
Ruminants over 3 months old being raised for slaughter and mink being raised for pelt production	60,000	No more than 50 % of diet on dry weight basis
Poultry being raised for slaughter	100,000	No more than 50 % of diet on dry weight basis
All other species or classes of livestock and pet animals	10,000	No more than 50 % of diet on dry weight basis

4. Occurrence of fumonisins in feed materials

Fumonisins are unique amongst the mycotoxins in being almost exclusively contaminants of maize, rather than occurring in a wider range of cereals or other commodities (Bullerman and Tsai, 1994). Only incidentally fumonisins have been found in wheat, asparagus, tea, and cowpea (Trucksess, 2003). Extensive world-wide survey data (Placinta *et al.*, 1999) on fumonisins in maize indicate that the vast majority of maize is contaminated with fumonisins. It is in fact very difficult to obtain uncontaminated maize as even when contamination is not significant, fumonisins can still be found at low background levels. In general, where contamination is found, levels of fumonisins range from 0.02 mg/kg (the limit of detection in many investigations) to sometimes tens of mg/kg. In most samples, FB₁ was the most prevalent toxin, with co-occurrence of FB₂ and FB₃. For 21 countries in Africa, North- and South America, Asia, and Europe, FB₁ was reported at levels from 0.02 to 25.9 mg/kg with FB₂ co-occurring at levels from 0.05 to 11.3 mg/kg (Placinta *et al.*, 1999). Samples of maize and distiller's dried grains from Denmark showed levels for the sum of FB₁, FB₂ and FB₃, ranging from < 0.025 up to 1.93 mg/kg (Friis-Wandall, 2004). Most survey data that have been published were for raw maize, but the intended destination has not been specified and often sampling and analysis was confined to materials intended for human consumption. However, animal feed in South Africa was reported to contain 4.0 to 11.0 mg/kg of FB₁ (Dutton and Kinsey, 1995), from Uruguay from 0.2 to 6.3 mg/kg (Pineiro *et al.*, 1997). Lower levels were reported in samples of poultry feed (0.02 - 0.26 mg/kg) from India (Shetty and Bhat, 1997). In contrast, Jindal *et al.* (1999) reported FB₁ concentrations in maize samples from India up to 87 mg per kg; whereas mixed poultry feed samples contained maximum concentrations of 28 mg FB₁ per kg feed. In 35 samples of pig feed from France prepared with home-grown maize, fumonisins were found in all samples at levels up to 2.1 mg/kg for FB₁ and 0.9 mg/kg for FB₂ (Dragoni *et al.*, 1996). In Poland, in 1997 fumonisins were detected in

78 samples of poultry mixed feed at levels from 0.010 to 0.178 mg/kg (Wisniewska-Dmytrow *et al.*, 2004).

In studies on the fate of fumonisins during dry milling of maize when the contamination was 5.09 mg/kg in the raw maize, levels of 9.5 mg/kg, 8.1 mg/kg and 6.8 mg/kg were found in the germ, bran and animal feed flour respectively, whilst levels were reduced to 0.42 mg/kg, 1.0 mg/kg and 0.45 mg/kg in the large grits, small grits and flour respectively (Brera *et al.*, 2004). Thus, the fractions destined for animal feed can be expected to contain higher levels of fumonisins than the raw materials. Fumonisins in maize components of animal feed were found at average levels of 24 mg/kg, 8.1 mg/kg, 5.7 mg/kg and 1.1 mg/kg in samples of maize screenings, maize meal, maize germ and maize germ bran respectively (Scudamore *et al.*, 1998). A similar picture was found when 27 of 32 samples of maize gluten used as raw ingredients for animal feed were found to contain FB₁ at levels from 0.1 to 4.5 mg/kg (Scudamore *et al.*, 1997). Maize germ, screenings and other maize derived fractions were similarly contaminated at levels up to 1.1 mg/kg, 2.7 mg/kg and 1.0 mg/kg respectively. The concentration of maize in the final feed was not reported. Information about the possible occurrence of fumonisins in silage is slender, but incidental studies suggest that maize silage may be contaminated with fumonisins at low levels (up to approximately 0.6 mg FB₁/kg) (Kim *et al.*, 2004).

The most recent compilation of data for fumonisins in cereals in Europe can be found in the SCOOP Report on *Fusarium* toxins (EC, 2003a). As the SCOOP Report on *Fusarium* toxins primarily focussed on assessing human exposure to fumonisins and other *Fusarium* toxins, inevitably the analysis centred on grain and grain products presumably destined for human food.

5. Estimating the intake of fumonisins by farm livestock

Maize and maize based feedstuffs are extensively used in feeding of farm animals. The main feedstuffs, which are made of maize, are maize grain, maize silages (whole plant, corn cob mix (CCM), maize stover) and products of the refining industry. Maize oil, maize gluten, maize germ meal and maize germ bran are the most important maize by-products in animal feeding.

In ruminant nutrition, whole plant maize silage is a basic component of the daily ration in many farms. Its proportion comprises usually between approximately 30 and 50 % of the daily ration, but it can be fed up to approximately 80 %, especially to beef cattle. Fumonsin degrading microorganisms have been isolated from silage (Camilo *et al.*, 2000), but it is not known if this degradation is of any significance for reduction of fumonisin concentrations in silage. Additionally, maize grain is a common component of the concentrate portion and might reach up to approximately 20 % of the total daily dry matter intake.

Maize grain is a basic component in diets for monogastric animals because of its high energy content. In fattening animals (broilers, pigs and turkeys), its dietary proportion is usually higher at the beginning of the fattening period than in the finishing period. Starter diets might

contain up to 70 % maize grains. In contrast, the maize grain content in finisher diets is limited up to approximately 20 % in most feeding systems.

On a dry matter basis, CCM can replace maize grain in most situations, both in ruminants and in monogastric animals.

Maize oil can generally be used in preparing of supplementary feedingstuff for nutritional or technological reasons (dust binding). The plant oil proportion is usually not higher than 3 to 5 % of the supplementary feedingstuff.

The proportion of maize gluten, maize germ meal and maize germ bran in diets for ruminants and monogastric animals accounts usually for less than 20 % of the daily dry matter intake.

Potential intakes that would arise at different levels of contamination of complete diets for pigs may be calculated on the basis that young, rapidly growing animals daily consume an amount of feed equivalent to approx. 10 % of their body weight, declining to approx. 5 % in adult animals. If it is assumed that the complete diet contains the hypothetical levels of up to 1 mg/kg feed, intake by young animals fed exclusively on such diets would be less than 0.1 mg/kg b.w./day.

6. Adverse effects on livestock

Intoxications following fumonisin exposure have been described for various animal species, and the differences in sensitivity and clinical symptoms are described below. Culture material of *Fusarium* has been used as the source of FB₁ in most of the feeding studies cited below. The culture material may contain also FB₂ and FB₃, but this has not been investigated in all cases, and hence the described pathological alterations might be attributable to the entire group of *Fusarium verticillioides* toxins.

6.1. Adverse effects in pigs

Fumonisin toxicosis in pigs is characterised by pulmonary, cardiovascular and hepatic symptoms. Moreover, hyperplastic oesophagitis, gastric ulceration, hypertrophy of the heart and hypertrophy of the pulmonary arteries have been described (Casteel *et al.*, 1994; Gumprecht *et al.*, 1998, 2001; Smith *et al.*, 1996, 1999). Lethal pulmonary oedema and hydrothorax has been observed in pigs exposed to feed containing > 12 mg FB₁/kg feed (corresponding to 0.6 mg/kg b.w./day) (Haschek *et al.*, 2001). Gross pathology reveals a severe pulmonary oedema (heavy, wet lungs) with widened interlobular septa, but without further signs of inflammation. When exposure was consistent over a period of 8 weeks, levels as low as 1 mg FB₁/kg feed have produced proliferation of the connective tissue, primarily around the lymphatic vessels and in the subpleural and interlobular connective tissue, extending into the peribronchial and peribronchiolar area. However, these alterations were not accompanied by clinical signs (Zomborszky-Kovács *et al.*, 2002a,b). These changes were seen in one of 4 animals at the lowest level of 1 mg/kg feed, 2 of 5 animals at 5 mg/kg feed and 3 of 4 animals at 10 mg/kg feed. The weight of the lungs of the pigs from the 5 and 10 mg/kg feed groups showed also a significant dose-dependent increase.

It has been suggested that the pulmonary injury is preceded by cardiovascular abnormalities and haemodynamic changes with pulmonary hypertension and left heart insufficiency (Smith *et al.*, 1999).

When pigs are exposed to fumonisins they develop also hepatic injury with hepatic necrosis and cholestasis. Affected animals become anorexic; show signs of encephalopathy, loose body weight and show hepatic nodular hyperplasia. These changes are accompanied by alterations in serum biochemical parameters, including an increase in circulating bile acids, elevated bilirubin concentration, and increased values for serum aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma-glutamyl transferase (γ GT) and lactate dehydrogenase (LDH) activity (Zomborsky-Kovács *et al.*, 2002a,b). These effects were concentration- and time-dependent. Motelin *et al.* 1994 found elevation of serum bilirubin, cholesterol, γ GT, ALP, alanine amino transferase (ALT), AST and arginase in pigs fed diets containing 101 or 175 mg FB₁/kg feed although levels were only significantly higher than control for bilirubin (at 5 days), and γ GT and ALT (at 14 days) in the group fed the highest FB₁ level. The findings were extrapolated to a so called “no observed effect level” NOAEL of < 12 mg FB₁/kg feed for ALP. In the feeding studies of Zomborszky-Kovács *et al.* (2002a,b) serum AST activities were only significantly higher at 4 weeks in the highest dosed groups administered 20 and 40 mg FB₁/kg feed. Elevated levels outside the normal physiological ranges were observed for ALP, AST and ALT in some of the animals from the groups fed 5 and 10 mg FB₁/kg feed that had pathological changes in the lungs. In contrast, an increase in serum cholesterol concentration was observed after exposure to ≥ 1 mg pure FB₁/kg feed to male pigs for 2 weeks (Rotter *et al.*, 1996). It was, however, not significantly higher in the 1 and 10 mg FB₁/kg feed group after 8 weeks.

A dose- and time dependent increase in the concentration of free sphinganine in serum and tissues is also observed early resulting in an increase in the Sa:So (sphinganine:sphingosine) ratio. Particularly in lung, liver and kidney this ratio is increased and significant changes have been observed after exposure to 5 mg FB₁ per kg feed (corresponding to an exposure of 0.2 mg/kg b.w./day) for a period of two weeks. Riley *et al.* (1993) found elevated free sphinganine in liver, lung and kidney tissues from pigs if the animals were exposed to concentration ≥ 23 mg total FB₁ + FB₂ per kg feed, and an increased Sa:So ratio in serum from pigs occurred when concentrations were ≥ 5 mg/kg feed. Rotter *et al.* (1996) found the Sa:So ratio to be increased in lung, kidney and liver from pigs fed 10 mg (10 ppm) but not 1 mg (1 ppm) pure FB₁/kg feed. Increased serum Sa:So ratios were found by Zomborszky-Kovács *et al.* (2002a) in pigs fed a rations with ≥ 5 mg/kg feed, but not in the group fed 1 mg FB₁/kg feed.

Under field conditions, the increase in the Sa:So ratio can be used to establish a diagnosis, as this phenomenon is unique for a fumonisin toxicosis (Riley *et al.*, 1993). At the same time alterations in the Sa:So ratio in organs are a sensitive biomarker of the onset of adverse effects. Hence monitoring of the Sa:So ratio (for example in serum or urine samples) has a dual function in monitoring exposure and assessing the onset of adverse effects.

In vitro studies with different cell cultures have confirmed the unique (diagnostic) value of the Sa:So ratio, which may also account for cellular apoptosis and necrosis of alveolar macrophages and endothelial cells in lung tissues of pigs (Zomborsky-Kovács *et al.*, 2002b). These latter findings correspond to previous data in mice (Martinova *et al.*, 1995), but are particularly relevant to pigs as these animals - in contrast to other species - have high numbers of macrophages residing in the lung, serving as first line of defence towards infectious agents, comparable to the function of Kupffer cells in the liver. Immune-modulatory effects have been described in pigs (Osborne *et al.*, 2002) but also in chickens (Li *et al.*, 1999; Marijanovic *et al.*, 1991; Qureshi *et al.*, 1995), and in rodents (Tryphonas, 1997).

Considering the Sa:So ratio as the most sensitive parameter in the assessment of adverse effect exerted by fumonisins the lowest observed adverse effect level was found to occur when pigs were exposed to feed containing 5 mg of fumonisins per kg feed (which is corresponding to approximately 0.2 mg/kg b.w./day). Lung lesions that are typical for fumonisins toxicity in pigs were observed at a dose of 0.4 mg/kg b.w./day (Zomborsky-Kovács *et al.*, 2002a, Riley *et al.*, 1993).

6.2. Adverse effects in poultry

Poultry seem to be less sensitive to fumonisin exposure than pigs and horses (see below) but only a few studies testing high dosages of fumonisins are available (Bryden *et al.*, 1987; Brown and Rottinghaus, 1994). In a feeding experiment, one-day old **male broiler chickens** were exposed for a period of 14 days to either 125 or 274 mg purified FB₁/kg feed. Reduced weight gain was observed, which was more pronounced in another trial where culture material containing also FB₂ was used (Javed *et al.*, 1993). The results of the same study indicate that younger chickens are more sensitive than older animals and spontaneous death was only observed during the first three days of life. A no-effect level for chickens could not be established from these experiments.

In an early study (Ledoux *et al.*, 1992) day-old broiler chickens were fed diets containing 0, 100, 200, 300, or 400 mg FB₁ from culture material per kg feed for 21 days. Body weight and average daily weight gain decreased with increasing FB₁ concentration and the weight of liver, proventriculus and gizzard increased. Histological lesions in livers were also seen in the birds fed FB₁. Serum calcium, cholesterol, and AST levels increased at the higher FB₁ levels.

In a later study (Ledoux *et al.*, 1996) *F. moniliforme* culture material containing total amounts of fumonisins (FB₁, FB₂ and FB₃) ranging between 33 and 627 mg/kg feed was given to one-day old chickens for a period of 21 days. Birds showed a dose-dependent reduced weight gain and reduced feed conversion. Hepatocellular hyperplasia progressed from mild (99 and 132 mg/kg dose groups) to moderate to severe, (330 mg/kg group) to severe at the two highest concentrations (429 and 627 mg/kg, respectively). From these data, US-FDA (2001) deduced a safe level of 66 mg/kg feed of FB₁ + FB₂ + FB₃ for chickens and turkey poults, although stating clearly the limitations of this study, which was conducted only over a period of 21 days.

Weibking *et al.* (1993) fed day-old broiler chickens FB₁ from culture material at 7 levels from 75 to 525 mg/kg feed (total FB 89 - 681 mg/kg) feed for 21 days. All chicks fed diets with fumonisins had increased serum sphinganine and serum Sa:So ratio. Feed intakes and body weight gains were lower at the two highest levels (450 and 525 mg FB₁/kg). Increased liver and kidney weight together with increased mean cell haemoglobin concentrations were also observed at those levels. Histological liver lesions were seen in chickens fed ≥ 225 mg FB₁/kg feed.

Broiler chickens (5 replicates of 6 birds/treatment) have also been fed purified FB₁ at 0, 20, 40, and 80 mg/kg feed for 21 days from day 1 (Henry *et al.*, 2000). No effect was seen on body weight and growth. Liver sphinganine concentration and the liver Sa:So ratio were significantly higher at all concentrations tested and increased with the FB₁ concentration, but the serum Sa:So ratio was only elevated in the group fed 80 mg FB₁ in the feed. Total liver lipids were lower in chickens fed the two highest FB₁ levels. Chickens fed the highest FB₁ level had also significantly higher serum GOT:ASP ratio, but cholesterol, ALP and LDH were not affected.

With the aim to evaluate the immune response in chickens, FB₁ through culture material was given to one-day old chickens at feed concentrations of 50, 100 or 200 mg/kg. Three weeks later the animals were challenged intravenously with either *E. coli* or inactivated Newcastle Disease Virus vaccine and either systemic bacteraemia or primary and secondary antibody titres were measured. The results suggested that FB₁ is immunosuppressive in chickens when fed 200 mg FB₁/kg diet (Li *et al.*, 1999).

In a chronic feeding study with broiler chickens and **turkeys** with *Fusarium moniliforme* culture material, representing concentrations of 25 or 50 mg FB₁/kg feed, turkeys did show a significantly lower feed intake when exposed to 50 mg FB₁/kg diet, whereas broiler chickens were not affected (Broomhead *et al.*, 2002). These findings point towards species differences in sensitivity.

Turkeys have also been fed diets containing 75, 150, 225, or 300 mg FB₁ from culture material per kg feed for 21 days (Weibking *et al.*, 1995). The lowest concentration corresponding to a daily dose of approximately 9 mg/kg b.w. on average. Dose-dependent decreases in feed intake and body-weight gains were found together with increases in liver weight. Feed made from another culture material but with the same FB₁ concentrations gave different effects on the above-mentioned parameters. Serum Sa:So ratios were increased in all fumonisin fed groups with no difference due to the culture material used. Hepatocellular hyperplasia was observed in all FB₁ treated groups.

Peking ducklings fed rations containing 100, 200 or 400 mg FB₁/kg feed (corresponding to a calculated value of 121, 241, or 482 total FB, respectively) from culture material for 21 days (Bermudez *et al.*, 1995) had a dose-dependent decrease in feed intake and weight gain. Increased absolute organ weights were found for liver, heart, kidney, pancreas and proventriculus with increasing FB₁ levels. Liver Sa:So ratio was increased for all FB₁ fed groups. Two of eight ducklings in the highest group died prior to the study termination.

In **Mallard ducks** given a daily dose of 0, 5, 15 or 45 mg/kg b.w. of FB₁ from culture material extracts for 12 days, an increase in the Sa:So ratio in the liver was observed in all groups and serum biochemistry indicated liver toxicity (Bailly *et al.*, 2001; Tran *et al.*, 2003, 2005). As the onset of these alterations varied in time, the authors concluded that fumonisins exert more prominent effects when ingested at a lower dose for a long time, rather than when ingested at a higher dose for a short period (Tran *et al.*, 2003). Drug metabolising enzyme activities in liver and kidney were increased in ducks from the fumonisin fed groups (Raynal *et al.*, 2001).

In conclusion, available data suggest that in broiler chickens the lowest observed adverse effect level is approximately 2 mg/kg b.w./day (calculated from Henry *et al.*, 2000). Data for ducklings and turkeys suggest that these species are not more sensitive than chickens, as LOAELs were 5 mg/kg b.w./day for Mallard ducks, 17 mg/kg b.w./day for Peking ducklings, and 9 mg/kg b.w./day for turkeys. It should be noted that these levels represent the lowest doses tested.

6.3. Adverse effects in ruminants

In contrast to many other mycotoxins FB₁ is incompletely degraded by the forestomach flora in ruminants (Gurung *et al.*, 1999; Smith and Thakur, 1996; Prelusky *et al.*, 1996a). Rice and Ross (1994) described initially increased concentrations of aminopolyols and aminopentols, as metabolites of FB₁ in the faeces of sheep and cattle. Later studies by Smith and Thakur (1996) and Caloni *et al.* (2002) found that FB₁ is eliminated mainly unmetabolised. Signs of intoxications have been reported in cattle, sheep and goats exposed to fumonisin contaminated feed materials:

Ingestion of feed containing 75 mg FB₁/kg feed daily for 14 days by Jersey **cows** increased serum cholesterol concentration and decreased feed intake and milk production (Richard *et al.*, 1996). Feed containing on an average 94 mg FB₁/kg feed was given daily for 253 days to Holstein steers. The treatment increased serum AST and γ GT activities and induced mild histological evidence of hepatocellular injury and biliary epithelial hyperplasia (Baker and Rottinghaus, 1999).

Eighteen feeder calves were fed diets containing low and high (26 respectively 105 mg/kg FB₁ or 33 respectively 148 mg/kg total FB) fumonisin levels based on corn screening during 31 days (Osweiler *et al.*, 1993). There was no effect on feed intake or weight gain. Significant increases in serum AST, γ GT, LDH, bilirubin and cholesterol occurred from day 10 through day 31 in the high dose group. Histological changes were also found in the livers from the high dose group. Lymphocyte blastogenesis was significantly impaired at the end of feeding in the high dose group. Milk-fed calves were intravenously administered FB₁ at 1 mg/kg b.w. daily during 7 days (Mathur *et al.*, 2001). They developed liver and kidney lesions with increased serum AST, ALP, γ GT, and sorbitol dehydrogenase. Both, free sphinganine and the sphingosine levels in most tissues increased, except for brain where sphingosine was not increased. The highest Sa:So ratio was found in liver and kidney while brain had the lowest.

When **lambs** (average b.w. 32 kg) were dosed intra-uminally with culture material at doses of 11.1, 22.2 or 45.5 mg/kg b.w. total fumonisins (FB₁, FB₂ and FB₃) for 4 consecutive days, spontaneous death occurred in the highest dose group (Edrington *et al.*, 1995). In the other animals, an increase in alkaline phosphatase, γ GT, AST and LDH activities could be observed. Moreover, serum cholesterol, triglyceride, urea nitrogen and creatinine levels were increased. Histological examination at the end of the trial revealed renal tubular necrosis and a mild hepatopathy, confirming previous findings of Kriek *et al.* (1991).

Weanling Angora **goats** tolerated feed containing 95 mg FB₁/kg feed, given for a period of 112 days, without clinical symptoms. The Sa:So ratio in the livers was significantly increased (Gurung *et al.*, 1998).

In conclusion, at a mean concentrations of 94 mg FB₁/kg feed (corresponding to 2.4 – 3.5 mg/kg b.w./day) biochemical changes occurred, indicating hepatocellular injury in steers. In angora goats, an increased Sa/So ratio occurred in the liver as first sign of adverse effect exerted by fumonisins, following a concentration of 95 mg FB₁/kg feed. Moreover one study seems to indicate that in feeder calves a no effect level of approximately 26 mg FB₁/kg feed (corresponding to 0.65 mg/kg b.w./day) could be expected.

6.4. Adverse effects in horses

The first syndrome attributed to fumonisins in the 1980ies was ELEM, equine leukoencephalomalacia, characterized by fatal necrotic lesions in the cerebrum. This syndrome appears to be unique for equidae, although brain lesions have been incidentally reported in other animal species as well. Like in pigs, fumonisins induce cardiovascular dysfunction in horses with decreased heart rates, lower cardiac output, and right ventricular contractibility which may be involved in the pathogenesis of the lesions in the central nervous system (Smith *et al.*, 2002). It has been hypothesized that ELEM is a result of cerebral oedema due to an inability to reduce the blood flow to the brain when the horse lowers its head to eat and drink (Constable *et al.*, 2000)

Horses fed with their concentrates culture material from different *Fusarium moniliforme* strains for 27 days at concentrations of 65, 130, and 200 mg FB₁/kg showed ELEM lesions at necroscopy (Goel *et al.*, 1996). Serum Sa:So ratios were significantly elevated at day 19. Moreover, sphinganine and sphingosine tissue levels were elevated in different parts of the brain and the intestines, when compared to healthy horses. The Sa:So ratios, however, were not significantly higher in these tissue.

Experimental studies revealed that the minimum intravenous dose of pure FB₁ that induces neurological abnormalities was 0.01 - 0.05 mg/kg b.w./day (Constable *et al.*, 2000). Assuming an oral bioavailability of 5 % in equidae, the equivalent oral dose would be 0.2 - 1.0 mg/kg b.w./day, to be considered as lowest adverse effect dose.

Exposure of horses to fumonisins also induces liver and kidney damage, associated with a significant increase in the serum concentration of free sphinganine. The increased Sa:So ratio and an increase in liver specific enzymes precede the clinical signs of ELEM.

Evaluation of many cases of ELEM in the USA indicate that the consumption of feed containing more than 10 mg FB₁/kg feed (0.2 mg/kg b.w./day) is associated with an increased risk for horses to develop ELEM, whereas at concentrations < 6 mg FB₁/kg of diet (equivalent to 0.12 mg/kg b.w./day) no increased risk for target animal species is assumed (Constable *et al.*, 2000; Ross *et al.*, 1991).

Recent experimental studies in which FB₁ was injected intravenously for a period of 28 days to horses, suggest a NOAEL of 0.01 mg/kg b.w. based on the identifiable signs of neuronal abnormalities (Foreman *et al.*, 2004). The NOEL for biochemical abnormalities in blood serum exceeded 0.2 mg/kg b.w./day (Constable *et al.*, 2000; FAO/WHO, 2001).

Additional experiments showed that ponies (n = 5), fed concentrates that contained 8 mg/kg FB₁ (and 2.56 mg/kg FB₂) originating from contaminated maize screening, in quantities corresponding to 0.8 % of their body weight (114 - 186 kg) for 122 days followed by 58 days at 1.6 % of body weight (Wilson *et al.*, 1992) developed periodically neurological disturbances during the entire experimental period. At the end of the experiments animals were sacrificed. With gross pathology, no visible brain lesions were observed in any of the ponies. Histopathological examinations revealed the abundant presence of brain lesions similar to those found in horses in all ponies. In conclusion, equidae, and horses in particular, seem to be very sensitive to Fumonisin.

6.5. Adverse effects in other animal species

6.5.1. Rabbits

Bucci *et al.* (1996) described leukoencephalomalacia and haemorrhages in the brain of rabbits similar to those observed in horses after exposure to fumonisins. Following intravenous injection of FB₁ nephrotoxic effects were also observed in rabbits (Gumbrecht *et al.*, 1995). In a teratogenicity study, dosages ranging from 0.1 to 1.75 mg/kg b.w. were given orally by gavage during gestation days 3 - 19. Maternal toxicity was observed at a dose of 0.25 mg/kg b.w./day, and foetal toxicity occurred at the lowest dose tested (0.1 mg/kg b.w.), but no major malformation could be observed (Bucci *et al.*, 1996; LaBorde *et al.*, 1997). These findings are agreement with experiments in Syrian hamsters (Penner *et al.*, 1998) and in rats, in which no malformations could be observed although following prenatal exposure to FB₁ the sphinganine levels and myelination were altered in various brain areas of developing rats (Know, 1995, 1997).

6.5.2. Mink

Adult female mink have been fed a diet that contained Fusarium culture material that provided a concentration of 89 mg FB₁/kg or 108 mg total FB/kg during 87 days (Restum *et al.*, 1995). The fumonisin exposed mink showed a mild lethargy, but no other clinical signs or differences in feed consumption (first 2 week), body weights, or survivability were found. Several serum parameters e.g. cholesterol, bilirubin, ALP, ALT, AST were greater in the mink fed FB than in control. The effect of fumonisins on mink reproduction has also been studied (Powell *et al.*, 1996). Adult female mink were fed a low- or high-dose diet with

Fusarium culture material at concentrations of 86 mg FB₁/kg (115 mg total FB/kg) and 200 mg FB₁/kg (254 mg total FB/kg) respectively from two weeks prior to breeding through gestation and lactation. Only 58 % of the mated females whelped in the high dose group compared to 100 % in the low dose. The kitten's body weight at birth showed a dose-dependent decrease and the number of stillborn kittens was directly proportional to the dose. No treatment-related gross or histological lesions were observed in the kittens.

The Sa:So ratio in urine from minks fed diets containing 86 or 200 mg FB₁/kg (115 or 254 mg total FB/kg) was increased 2 to 11-fold within 7 days as compared to control (Morgan *et al.*, 1997). Lower doses of fumonisins were not tested.

6.5.3. Fish

Fumonisin are recognized to be toxic for fish, however, only few data have been published. Groups of catfish (*Ictalurus punctatus*) have been fed diets formulated by inclusion of *Fusarium* culture material from maize to contain FB₁ at 20, 80, 320, and 720 mg/kg during 10 weeks (Lumlertdacha *et al.*, 1995). The maize culture material also contained FB₂ (22 % of FB₁). Survival was 100 % for fish fed 20 mg/kg FB₁, but weight gain was significantly decreased by 15 % compared to control, and liver lesions were noted histologically. Catfish has also in another study been fed FB₁ from *Fusarium* cultured maize (Li and Robinson, 1995). There is no information on FB₂ or FB₃ levels. Eight groups of 20 fishes were fed 0, 0.7, 2.5, 5.0, 10.0, 20.0, 40.0 or 240.0 mg FB₁/kg feed, respectively, for 12 weeks. Decreased weight gain, feed consumption and feed conversion ratio as well as histological changes were found at concentrations ≥ 40 mg FB₁/kg feed. From this study an apparent no effect level of 20 mg/kg feed could be deduced.

In young carps, exposure to contaminated feed (equivalent to a daily intake of 0.5 to 50 mg FB₁/kg b.w.) resulted in a loss of body weight and alterations of haematological and biochemical parameters, indicating liver and kidney damage (Pepeljnak *et al.*, 2003). Additional studies in one-year old carps demonstrated pathological alterations in liver, endocrine and exocrine pancreas, kidney, heart and brain already following exposure to 10 mg FB₁/kg diet (Petrinec *et al.*, 2004).

Nile tilapia (*Oreochromis niloticus*) has also been fed FB₁ from culture material in their diet for 8 weeks to study the effect on growth, histological and biochemical changes (Tuan *et al.*, 2003). Groups of 20 fishes were fed FB₁ at levels of 10, 40, 70 and 150 mg/kg feed. Average weight gain was decreased at levels ≥ 40 mg FB₁/kg. Haematocrit was reduced only in fish fed diets containing 150 mg FB₁/kg. The Sa:So ratio in liver increased dose-dependently with insignificant increase in the highest dose group. Mortality was low in all groups and no histopathological lesions were observed.

The experimental data with catfish and Nile tilapia suggest a No Effect Level of 20 mg/kg feed. Recent studies with carps indicated that signs of toxicity can be observed following to exposure of 10 mg FB₁/kg feed (Petrinec *et al.*, 2004).

6.5.4. Rodents

Numerous studies have been conducted in rodents to describe the acute and chronic toxicity of fumonisins and to define the pathological alterations associated with exposure to purified toxins or fungal culture material. These data have been recently summarized (FAO/WHO, 2002). In rats, initially the liver was identified as major target organ of fumonisins toxicity, as the application of FB₁ resulted in single cell necrosis, liver fibrosis, bile duct hyperplasia and hepatocellular carcinomas (Gelderblom *et al.*, 1988, Gelderblom *et al.*, 1991). The apparent no-effect-level varies, however, considerable between individual studies, depending on the strain, gender and diet used. Furthermore, various studies indicated that pathological changes in the kidneys precede liver alterations and occur at lower concentrations of fumonisins (see Table 1).

7. Toxicokinetics, metabolism and tissue distribution

Fumonisin are poorly absorbed and the oral bioavailability remains generally below 5 % for FB₁, and seems to be even lower for FB₂. The absorbed fractions are rapidly distributed and eliminated. Studies in rats with radio-labelled material showed rapid distribution and renal elimination rates ($t_{1/2el} = 40$ minutes after intravenous injection of FB₁). Tissue levels were found to be highest in kidneys, followed by the liver (Norred *et al.*, 1993). FB₁ is glucuronidated and excreted with bile fluid (approximately 1.4 % of the dose), which may result in entero-hepatic re-circulation and a delayed terminal elimination phase (Dantzer *et al.*, 1999).

In a more recent study with Wistar rats, dosed orally with different concentrations of FB₁, a rapid absorption (T_{max} after 1 hour) and an apparent elimination plasma half-life of 3.15 hours, was calculated. The elimination half-life was measured also in the liver (4.1 hours), and in the kidneys (7.1 hours). Taken together, these data provide no evidence for tissue accumulation of FB₁ (Martinez-Larranga *et al.*, 1999).

In a kinetic study with pigs in which radio-labelled FB₁ was used, the apparent plasma half-lives were $t_{1/2\alpha} - 2.2$ min., $t_{1/2\beta} - 10.5$ min, and $t_{1/2\gamma} - 192$ min (assumed to result from enterohepatic re-circulation) after intravenous application (Prelusky *et al.*, 1994). Recovery of FB₁ in biliary fluids represented 70.8 % of the intravenous dose, thus being significantly higher than the biliary excretion in rats. Oral bioavailability from parallel studies with intragastric application indicated an oral bioavailability of FB₁ of 3 - 6 % of the administered dose (Prelusky *et al.*, 1996b).

FB₁ may be hydroxylated, but this limited hydroxylation seems to take place pre-systemically, as studies with bovine liver microsomes did not show any significant transformation of FB₁ (Spotti *et al.*, 2001). A poor rate of hydroxylation was also observed in the rumen fluid (Caloni *et al.*, 2000). Although the biotransformation of FB₁ is very limited, it has been shown to inhibit certain P450 enzymes, both *in vivo* and *in vitro* (Spotti *et al.*, 2000).

8. Carry-over and residues

Several studies have been published on the possibilities of carry-over of fumonisins from feed into animal products, such as milk, meat and eggs.

In a study with ^{14}C -FB₁, **dairy cows** were dosed orally (1 or 5 mg FB₁/kg b.w.) and intravenously (0.05 or 0.2 mg FB₁/kg b.w.) (Prelusky, 1994). FB₁ residues in milk were detected at negligible levels (5 - 6 ng/ml). In another study (Richard *et al.*, 1996) fungal culture material with FB₁, FB₂ and FB₃ was mixed into the total diet of two lactating cows. The two cows consumed an average of 3 mg FB₁/kg body weight per day during 14 days. In this period milk samples were collected and investigated. Fumonisin was not found in milk (LOD 5 ng/ml). In another study, three lactating cows were given an intravenous dose of 30 mg FB₁ (Hammer *et al.*, 1996). Analysis of milk sample showed some positive samples, and a maximum rate of 0.11 % was calculated. Spotti *et al.* (2001) studied the FB₁ carry-over into milk in the isolated perfused bovine udder *ex vivo*. FB₁ (2 mg) was injected into the perfusion fluid of 3 udders, and milk and perfused serum levels were analysed over a period of 150 minutes. Carry-over from blood-to-milk was estimated to be in the range 0.001 - 0.004 %. Previous studies had already indicated a very limited carry-over of FB₁ into the milk of lactating sows (Becker *et al.*, 1995).

Thirty weeks old **laying hens** received an intravenous (2 mg/kg b.w.) or an oral dose (2 mg/kg b.w.) of ^{14}C -FB₁ (Prelusky, 1994). Measurements showed that almost all of the radioactivity was recovered in the excreta of the hens and that its level in the different organs and tissues was negligible (< 10 - 15 ng FB₁/g tissue), except for some localization in the liver (530 ng/g) and kidneys (210 ng/g). Moreover, eggs were collected and separated into yolk, albumin and eggshells. The residue levels in these separated parts of eggs were negligible (< 10 - 15 ng fumonisin/g).

In a study with **pigs**, dosed 2 - 3 mg ^{14}C -FB₁ for a period of 24 days, concentrations of 160 and 65 ng/g were found in liver and kidney respectively. Muscle and fat tissue were free of residues of FB₁ (Prelusky *et al.*, 1996b). A more recent study on residue formation of FB₁ in porcine tissues showed that after oral administration of a very high (experimental) dose (100 mg FB₁ per animal per day) for 5 - 11 days, residues of FB₁ can be detected in the kidneys (833 ng/g), liver (231 ng/g), lung (170 ng/g), spleen (854 ng/g), muscle (26 ng/g) and fat (2 ng/g). In a final trial on which pigs were exposed to 22 mg of FB₁ per kg feed for five months, no residues were found in the kidneys (LOD 5 µg/kg tissue) (DeLiguoro *et al.*, 2004).

The animal studies carried out to determine the potential carry-over of fumonisins from animal feed into animal products all indicated that minor tissue levels of FB₁ can be detected in various tissues, but the low carry-over rate suggests that these low residue levels do not contribute substantially to human exposure (see also below).

9. Human dietary exposure

Estimates of dietary intakes of fumonisin based on national estimates have been presented by FAO/WHO, indicating an exposure from 0.02 µg/kg b.w./day to 0.2 µg/kg b.w./day, thus remaining below the PMTDI of 2 µg/kg b.w./day set by JECFA (FAO/WHO, 2001) and the TDI set by SCF (EC, 2003b). In the JECFA evaluation only the consumption of contaminated maize or maize-containing food products was considered, as the contributions of other commodities to the intake of fumonisins are too low and too variable to affect long-term exposure significantly.

Data from the EU SCOOP Task (EC, 2003a) showed that the average daily intakes are well below the tolerable intake (0.8 % - 13.2 % of the TDI for the whole population and 0.1 - 14.1 % of the TDI for the adults). Higher intakes were noted for young children (22.3 % of the TDI). Cereals represent the major source of intake of fumonisins. Among cereals, maize and wheat dominate as main contributors to the total intake.

A total diet study has been performed in France on the basis of samples purchased in 2000 and 2001 (Leblanc *et al.*, 2005). The estimated total average intake of fumonisins of the French population is 14 ng/kg b.w./day for adults and 46 ng/kg b.w./day for children of an age of 3 to 14 years. The 95th percentile exposure is respectively 64 ng/kg b.w./day for adults (3 % of the TDI) and 175 ng/kg b.w./day for children (9 % of the TDI). In the category food of animal origin only edible offals have been analysed and levels ranging from 0.09 to 0.12 µg/kg have been found contributing for less than 3 % to the total fumonisin exposure.

CONCLUSIONS

- Fumonisins are a distinct group of mycotoxins produced by various *Fusarium* species, especially from *Fusarium verticilloides*, invading predominantly maize plants. Fumonisins have been detected worldwide in maize and maize-based products. However, data on the occurrence of fumonisins in feed materials are scarce, and fumonisin concentrations vary from a few µg/kg to tens of mg/kg.
- Fumonisin B₁, considered to be the most prevalent and most toxic derivative, is a prototypic inhibitor of cellular sphingosine (sphinganine) N-acetyltransferase. Inhibition of this enzyme results in an accumulation of sphinganine (Sa) and sometimes also sphingosine (So) and a depletion of complex sphingolipids in eukaryotic cells. This results in increased oxidative stress, impairment of the regulation of the cell cycle and cellular differentiation, and cellular apoptosis or necrosis. The altered Sa:So ratio which is a unique indicator of fumonisin exposure serves also sensitive biomarker for the onset of adverse effects.
- Intoxications associated with the occurrence of fumonisins in animal feeds comprise distinct syndromes such as ELEM (equine leukoencephalomalacia), PPE (porcine pulmonary edema), as well as dose dependent hepatocellular injury with enzyme leakage and increased serum cholesterol levels. Moreover, progressive renal tubular

necrosis (being also the first signs of toxicity in rodent studies) has been observed in all animal studies where it was tested.

- Most reports on occurrence and toxicity refer to concentrations of fumonisin B₁ in the diet. However, it can not be excluded that other fumonisins and even other toxins produced by *Fusarium verticillioides* were present in culture materials used for diet composition, and may have contributed to the observed effects.
- Experimental data from rabbits (as well as from studies in rodents and minks) provide no evidence for teratogenic effects. Fumonisin B₁ is carcinogenic in rodents, however it is devoid of significant genotoxic activity. Animal experiments suggest that fumonisins act as tumour promoters.
- In target animal species, the lowest observed adverse effect levels (LOAEL) for fumonisin B₁ were seen in horses and pigs, showing fumonisin-related alterations at a dose of approximately 0.2 mg/kg b.w./day. In calves, the apparent NOAEL was 0.6 mg/kg b.w./day, whereas in adult ruminants the LOAEL was 2.4 mg/kg b.w./day. In poultry chicks a LOAEL of 2 mg/kg b.w. could be derived from the available experimental data. Data from ducks, ducklings and turkeys do not provide evidence that these species are more sensitive than chickens. Data from catfish and Nile tilapia suggest a NOAEL corresponding to 20 mg/kg feed, whereas in carps a LOAEL of 10 mg/kg feed was described.
- Available data on carry-over of fumonisins from animal feeds into edible tissues, including milk and eggs, indicate that transfer is limited and thus residues in animal tissues contribute insignificantly to total human exposure.

RECOMMENDATIONS

- Analytical methods for the determination of the concentrations of fumonisin B₁ including its bound forms need to be developed and validated for maize-based feedingstuffs.
- More information is needed on the effects of fumonisins on farmed fish and on minor species, such as rabbits, goats, and mink to improve risk assessment for these species.

REFERENCES

- AOAC International, 2000. Including supplements. AOAC Official Methods of Analysis. Methods 995.15 “Fumonisin B₁, B₂ and B₃ in corn”; 2001.01 “Determination of fumonisin B₁ and B₂ in corn and cornflakes”; 2001.06 “Determination of total fumonisin in corn”. In: Chapter 49, Natural Toxins. Trucksess M.W. (ed). AOAC International, Gaithersburg, USA.
- Bailly, J.D., Benard, G., Jouglar, J.Y., Durand, S. and Guerre, P. 2001. Toxicity of *Fusarium moniliforme* culture material containing known levels of fumonisin B₁ in ducks. *Toxicology* 163(1):11-22.
- Baker, D.C. and Rottinghaus, G.E. 1999. Chronic experimental fumonisin intoxication of calves. *J Vet Diagn Invest* 11(3):289-292.
- Becker, B.A., Pace, L., Rottinghaus, G.E., Shelby, R., Misfeldt, M. and Ross, M.S. 1995. Effects of feeding Fumonisin B₁ to lactating sows and their suckling pigs. *American Journal of Veterinary Research* 56:1253-1258.
- Bermudez, A.J., Ledoux, D.R. and Rottinghaus, G.E. 1995. Effects of *Fusarium moniliforme* culture material containing known levels of fumonisin B-1 in ducklings. *Avian Dis* 39(4):879-886.
- Bolger, M., Coker, R.M., DiNovi, M., Gaylor, D., Gelderblom, W., Olsen, M., Paster, N., Riley, R., Shephard, G. and Speijers, G.J.A. 2001. In: Safety evaluation of certain mycotoxins in food: Fumonisin. Prepared by the 56th Meeting of the joint FAO/WHO Expert Committee on Food Additives (JECFA) (FAO/WHO 2001).
- Brera, C., Debegnach, F., Grossi, S. and Miraglia, M. 2004. Effect of industrial processing on the distribution of fumonisin B₁ in dry milling corn fractions. *Journal of Food Protection* 67:1261-1266.
- Broomhead, J.N., Ledoux, D.R., Bermudez, A.J. and Rottinghaus, G.E. 2002. Chronic effects of fumonisin B-1 in broilers and turkeys fed dietary treatments to market age. *Poult Sci* 81(1):56-61.
- Brown, T.P. and Rottinghaus, G.E. 1994. Fumonisin mycotoxicosis in broilers: performance and pathology. *Avian Disease* 36:450-454.
- Bryden, W.L., Love, R.J. and Burgess, L.W. 1987. Feeding grains contaminated with *Fusarium graminearum* and *Fusarium moniliforme* to pigs and chickens. *Australian Veterinary Journal* 64:225-226.
- Bucci, T.J., Hansen, D.K. and LaBorde, J.B. 1996. Leukoencephalomalacia and hemorrhage in the brain of rabbits gavaged with mycotoxin fumonisin B₁. *Nat. Toxins* 4(1):51-52.
- Bullerman, L.B. and Tsai, W.Y. 1994. Incidence and levels of *Fusarium moniliforme*, *Fusarium proliferatum* and fumonisin in corn and corn-based foods and feeds. *Journal of Food Protection* 57:541-546.
- Caloni, F., Spotti, M., Auerbach, H., Op den Camp, H., Gremmels, J.F. and Pompa, G. 2000. In vitro metabolism of fumonisin B₁ by ruminal microflora. *Vet Res Commun* 24(6):379-387.
- Caloni, F., Spotti, M., Pompa, G., Zucco, F., Stamatii, A. and De Angelis, I. 2002. Evaluation of Fumonisin B(1) and its metabolites absorption and toxicity on intestinal cells line Caco-2. *Toxicon* 40(8):1181-188.

- Camilo, S.B., Ono, C.J., Ueno, Y. and Hirooka, E.Y. 2000. Anti-Fusarium moniliforme activity and fumonisin biodegradation by corn and silage microflora. *Arquivos de Biologia e Tecnologia* 43(2):159-164.
- Casteel, S.W., Turk, J.R. and Rottinghaus, G.E. 1994. Chronic effects of dietary fumonisins on the heart and pulmonary vasculature of swine. *Fundamental and Applied Toxicology* 23:518 – 524.
- Ciacchi-Zanella, J.R. and Jones, C. 1999. Fumonisin B₁, a mycotoxin contamination of cereal grains and inducer of apoptosis via tumour necrosis factor pathway and caspase activation. *Food and Chemical Toxicology* 37:703-712.
- Collins T.F., Sprando R.L., Black, T.N., Shackelford, M.E., Laborde, J.B., Hansen DK, Eppley, R.M., Trucksess, M.W., Howard, P.C., Bryant, M.A., Ruggles, D.I., Olejnik, N. and Rorie, J.I. 1998. Effects of Fumonisin B₁ in pregnant rats. Part 2. *Food Chem. Toxicol.* 36:673-85.
- Constable, P.D., Foreman, J.H., Waggoner, A.L., Smith, G.W., Eppley, R.M., Tumbleson, M.E. and Haschek, W.M. 2000. The mechanism of fumonisin mycotoxicosis in horses. Draft report on USDA–CSREES Grant #928-39453, pp. 1–28.
- Dantzer, W.R., Hopper, J., Mullin, K., Hendrich, S. and Murphy P.A. 1999. Excretion of ¹⁴C-Hydrolyzed Fumonisin B₁ and ¹⁴C-Fumonisin B₁-fructose in Rats. *Journal of Agricultural and Food Chemistry* 47:4291-4296.
- De Liguoro, M., Petterino, C., Mezzalira, G., Tenti, S. and Ravarotto, L. 2004. Field observations in pigs exposed to fumonisin B1 contaminated feed. *Vet Hum Toxicol*, Dec; 46(6):303-305.
- Dragoni, I., Pascale, M., Piantanida, L. Trilly, Y. and Visconti, A. 1996. Occurrence of fumonisins in feedstuffs intended for pig consumption in Brittany (France). *Microbiologie, Aliments, Nutrition* 14:97-103.
- Dutton, M.F. and Kinsey, A. 1995. Occurrence of mycotoxins in cereals and animal feedstuffs in Natal, South Africa, 1994. *Mycopathologia* 131:31-36.
- EC (European Commission), 2000. Opinion of the Scientific Committee on Food on Fusarium Toxins. Part 3: Fumonisin B₁ (FB₁). Expressed on 17 October 2000. http://europa.eu.int/comm/food/fs/sc/scf/out73_en.pdf.
- EC (European Commission), 2003a. SCOOP task 3.2.10. Collection of Occurrence Data of *Fusarium* Toxins in Food and Assessment of Dietary Intake by the Population of EU Member States, Subtask III: Fumonisin. European Commission, Directorate-General Health and Consumer Protection, Brussels, 485-577. <http://europa.eu.int/comm/food/fs/scoop/task3210.pdf>.
- EC (European Commission), 2003b. Updated opinion of the Scientific Committee on Food on Fumonisin B₁, B₂ and B₃. Expressed on 4 April 2003. http://europa.eu.int/comm/food/fs/sc/scf/out185_en.pdf.
- Erdington, T.S., Kampsholtzapple, C.A., Harvey, R.B., Kubena, L.F., Elissalde, M.H. and Rottinghaus, G.E. 1995. Acute hepatic and renal toxicity in lambs dosed with fumonisin-containing culture material. *J Anim Sci* 73(2):508-515.
- Eriksen, G.S. and Alexander, J. 1998. Fusarium toxins in cereals- a risk assessment. Nordic Council of Ministers, TemaNord 502, Copenhagen, Denmark.
- FAPAS[®] (Food Analysis Performance Assessment Scheme), 2000. Fusarium Toxins, FAPAS[®] Series 22 Round 01, August 2000, Report 2201, Central Science Laboratory, Sand Hutton, York, UK.

- FAPAS[®] (Food Analysis Performance Assessment Scheme), 2001a. Fusarium Toxins, FAPAS[®] Series 22 Round 03, April 2001, Report 2203, Central Science Laboratory, Sand Hutton, York, UK.
- FAPAS[®] (Food Analysis Performance Assessment Scheme), 2001b. Fusarium Toxins, FAPAS[®] Series 22 Round 05, December 2001, Report 2205, Central Science Laboratory, Sand Hutton, York, UK.
- FAPAS[®] (Food Analysis Performance Assessment Scheme), 2002. Fusarium Toxins, FAPAS[®] Series 22 Round 08, November 2002, Report 2208, Central Science Laboratory, Sand Hutton, York, UK.
- FAPAS[®] (Food Analysis Performance Assessment Scheme), 2003. Fusarium Toxins, FAPAS[®] Series 22 Round 11, July 2003 to August 2003 Report 2211, Central Science Laboratory, Sand Hutton, York, UK.
- FAO (Food and Agriculture Organization), 1997. Worldwide Regulations for Mycotoxins 1995. A compendium. FAO Food and Nutrition Paper 64, Rome, Italy.
- FAO (Food and Agriculture Organization), 2004. Worldwide Regulations for Mycotoxins in food and feed in 2003. FAO Food and Nutrition Paper 81, Rome, Italy.
- FAO/WHO (Food and Agriculture Organization/World Health Organization), 2001. Safety evaluation of certain mycotoxins in food. Prepared by the Fifty-sixth meeting of the Joint FAO/WHO Expert Committee on Food Additives. WHO Food Additives Series, No. 47; FAO Food and Nutrition Paper 74, 2001.
- FAO/WHO (Food and Agriculture Organization/World Health Organization), 2002. Evaluation of certain mycotoxins in food. Fifty-sixth report of the joint FAO/WHO Expert Committee on Food Additives, WHO Technical Report Series 906, World Health Organization, Geneva, Switzerland.
- Foreman, J.H., Constable, P.D., Waggoner, A.L., Levy, M., Eppley, R.M., Smith, G.W., Tumbleson, M.E. and Haschek, W.M. 2004. Neurologic abnormalities and cerebrospinal fluid changes in horses administered fumonisin B1 intravenously. *J Vet Intern Med* 18(2):223-230.
- Friis-Wandall, S. 2004. Danish Plant Directorate. Personal communication.
- Gelderblom, W.C.A., Jaskiewicz, K., Marasas, W.F.O., Thiel, P.G., Horak, R.M., Vleggaar, R. and Kriek, N.P.J. 1988. Fumonisin - Novel mycotoxins with cancer-promoting activity produced by *Fusarium moniliforme*. *Applied and Environmental Microbiology* 54:1806-1811.
- Gelderblom, W.C.A., Kriek, N.P.J., Marasas, W.F.O. and Thiel, P.G. 1991. Toxicity and carcinogenicity of the *Fusarium moniliforme* metabolite, fumonisin B₁, in rats. *Carcinogenesis* 12:1247-1251.
- Gelderblom, W.C.A., Snyman, S.S., Lebepe-Mazur, S., Westhuizen, L. van der, Kriek, N.P.J. and Marasas, W.F.O. 1996. The cancer promoting potential of Fumonisin B1 in rat liver using diethylnitrosamin as cancer initiator. *Cancer Letters* 109:101-108.
- Goel, S., Schumacher, J., Lenz, S.D. and Kempainen, B.W. 1996. Effects of *Fusarium moniliforme* isolates on tissue and serum sphingolipid concentrations in horses. *Vet Hum Toxicol* 38(4):265-270.
- Gumprecht, L.A., Beaslet, V.R., Weigel, R.M., Parker, H.M., Tumbleson, M.E., Bacon, C.W., Meredith, F.I. and Haschek, W.M. 1998. Development of fumonisin-induced hepatotoxicity and pulmonary edema in orally dosed swine: morphological and biochemical alterations. *Toxicology-Pathology* 26:777-788.

- Gumbrecht, L.A., Marcucci, A., Weigel, R.M., Vesconder, R.F., Riley, R.T., Snowker, J.L., Beasley, V.R. and Haschak, W. 1995. Effects of intravenous Fumonisin B₁ in rabbits: nephrotoxicity and sphingolipid alterations. *Natural Toxins* 3:395-403.
- Gumprecht, L.A., Smith, G.W., Constable, P.C. and Haschek, W.M. 2001. Species and organ specificity of fumonisin-induced endothelial alterations: Potential role in porcine pulmonary edema. *Toxicology* 160(1-3):71-79.
- Gurung, N.K., Rankins Jr., D.L., Shelby, R.A. and Goel, S. 1998. Effects of Fumonisin B₁-contaminated Feeds on Weanling Angora Goats. *Journal of Animal Science* 76:2863-2870.
- Gurung, N.K., Rankins Jr., D.L. and Shelby, R.A. 1999. In vitro ruminal disappearance of fumonisin B-1 and its effects on in vitro dry matter disappearance. *Vet Hum Toxicol* 41(4):196-199.
- Hammer, P., Blüthgen, A. and Walte, H.G. 1996. Carry-over of fumonisin B₁ into the milk of lactating cows. *Milchwissenschaft* 51:691-695.
- Haschek, W.M., Gumprecht, L.A., Smith, G., Tumbleson, M.E. and Constable, P.D. 2001. Fumonisin toxicosis in swine: an overview of porcine pulmonary edema and current perspectives. *Environ Health Perspect* 109 Suppl 2:251-7.
- He, Q., Bhandari, N. and Sharma, R.P. 2002. Fumonisin B₁ alters sphingolipid metabolism and tumor necrosis factor alpha expression in heart and lung of mice. *Life Sciences* 71:2015-2023.
- Henry, M.H., Wyatt, R.D. and Fletchert, O.J. 2000. The toxicity of purified fumonisin B₁ in broiler chicks. *Poult Sci* 79(10):1378-84.
- Howard, P.C., Thurman, J.D., Lorentzen, R.J.M., Voss, K.A., Bucci, T.J. and Dooley, K.L. 1995. The induction of apoptosis in the liver and kidney of male and female F344 rats fed diets for 28 days containing the mycotoxin fumonisin B₁. *Proceedings American Association for Cancer Research* 36:785-786.
- Humpf, H.-U. and Voss, K.A. 2004. Effects of thermal food processing on the chemical structure and toxicity of fumonisin mycotoxins. *Mol Nutr Food Res* 48:255-269.
- IARC (International Agency for Research on Cancer), 1993. Toxins derived from *Fusarium moniliforme*: Fumonisin B₁ and B₂ and fusarin C. In: Some naturally occurring substances: Food items and constituents, heterocyclic aromatic amines and mycotoxins. International Agency for Research on Cancer, IARC Monograph on the Evaluation of Carcinogenic Risk to Humans, volume 56, pp, 445 – 466, International Agency for Research on Cancer, Lyon.
- IARC (International Agency on Research on Cancer), 2002. Summaries and Evaluations: Fumonisin B₁. Vol 82, p301. <http://www-cie.iarc.fr/htdocs/monographs/vol82/82-05.html>.
- Javed, T., Bennett, G.A., Richard, J.L., Dombink-Kurtzman, M.A., Cote, L.M. and Buck, W.B. 1993. Mortality in broiler chicks on feed amended with *Fusarium proliferatum* culture material or with purified fumonisin B₁ and moniliformin. *Mycopathologia* 123:171-184.
- Jindal, N., Mahipal, S.K. and Rottinghaus, G.E. 1999. Occurrence of fumonisin B₁ in maize and poultry feeds in Haryana, India. *Mycopathologia* 148:37-40.
- Kim, E.-K., Scott, P.M. and Lau, B.P.-Y. 2003. Hidden fumonisin in corn flakes. *Food Addit Contam* 20:161-169.
- Kim, E.-K., Maragos, C.M. and Kendra, D.F. 2004. Liquid chromatographic determination of fumonisins B-1, B-2, and B-3 in corn silage. *Journal of Agricultural and Food Chemistry* 52:196-200.

- Kriek, N.P.J., Kellerman, T.S. and Marasas, W.F.O. 1981. A comparative study of the toxicity of *Fusarium verticillioides* (= *F. moniliforme*) to horses, primates, pigs, sheep and rats. *Onderstepoort Journal of Veterinary Research* 48:129-131.
- Kwon, O.S. Schmued, L.C. and Slikker W. Jr. 1995. Fumonisin FB1 increases sphinganine (a precursor of ceramide synthesis) in the brains and spinal cord of developing rats. *The Toxicologist* 15:17-20.
- Kwon, O.S., Schmued, L.C. and Slikker W. Jr. 1997. Fumonisin B1 in developing rats alters brain sphinganine levels and myelination. *Neurotoxicology* 18:571-579.
- Laborde, J.B., Terry, K.T., Howard, P.C. Chen, J.J., Collins, T.F.X., Shackelford, M.E. and Hansen, D.K. 1997. Lack of embryotoxicity of fumonisin B₁ in New Zealand white Rabbits. *Fundamental and Applied Toxicology* 40:120-128.
- Lebepe-Mazur, S., Bal, H., Hopmans, E., Murogy, O. and Hendrich, S. 1995. Fumonisin B1 is fetotoxic in rats. *Veterinary and Human Toxicology* 37:126-130.
- Leblanc, J.Ch., Tard, A., Volatier, J.L. and Verger, P. 2005. Estimated dietary exposure to the principal food mycotoxins from the 1st French Total Diet Study. *Food Additives and Contaminants* - in press.
- Ledoux, D.R., Brown, T.P., Weibking, T.S. and Rottinghaus, G.E. 1992. Fumonisin toxicity in broiler chicks. *J Vet Diagn Invest* 4(3):330-333.
- Ledoux, D.R., Bermudez, A.J. and Rottinghaus, G.E. 1996. Effects of feeding *Fusarium moniliforme* culture material, containing known levels of fumonisin B₁, in the young turkey poult. *Poult Sci* 75:1472-1478.
- Li, M.H., and Robinson, E.H. 1995. Catfish growth not affected by low levels of mycotoxins produced by the mold *Fusarium moniliforme*, new research indicates. *The Catfish Journal* June, p. 16.
- Li, Y.C., Ledoux, D.R., Bermudez, A.J., Fritsche, K.L. and Rottinghaus, G.E. 1999. Effects of fumonisin B-1 on selected immune responses in broiler chicks. *Poult Sci* 78(9):1275-1282.
- Lumlertdacha, S., Lovell, R.T., Shelby, R.A., Lenz, S.D. and Kempainen, B.W. 1995. Growth, hematology, and histopathology of channel catfish, *Ictalurus punctatus*, fed toxins from *Fusarium moniliforme*. *Aquaculture* 130(2-3):201-218.
- Marijanovic, D.R., Holt, P., Norred, W.P., Bacon, C.W., Voss, K.A. and Stancel, P.C. 1991. Immunosuppressive effects of *Fusarium moniliforme* corn cultures in chickens. *Poult Sci* 70:1895-1901.
- Martinez-Larranaga, M.R., Anadon, A., Diaz, M.J., Fernandez-Cruz, M.L., Martinez, M.A., Frejo, M.T., Martinez, M., Fernandez, R., Anton, R.M., Morales, M.E. and Tafur, M. 1999. Toxicokinetics and oral bioavailability of fumonisin B₁. *Veterinary and Human Toxicology* 41(6):357-362.
- Martinova, E.A. and Merrill, A.H.Jr. 1995. Fumonisin B1 alters sphingolipid metabolism and immune function in BALB/c mice: immunological responses to fumonisin B₁. *Mycopathologia* 130(3):163-70.
- Mathur, S., Constable, P.D., Eppley, R.M., Waggoner, A.L., Tumbleson, M.E. and Haschek, W.M. 2001. Fumonisin B-1 is hepatotoxic and nephrotoxic in milk-fed calves. *Toxicol Sci* 60(2):385-396.
- Merrill, A.H.Jr., Wang, E., Vales, T.R., Smith, E.R., Schroeder, J.J., Menaldino, D.S., Alexander, C., Crane, H.M., Xia, J., Liotta, D.C., Meredith, F.I. and Riley, R.T. 1996. Fumonisin toxicity and sphingolipid biosynthesis. *Advances in Experimental Medicine and Biology* 392:297-306.

- Merrill, A.H.Jr., Schmelz, E.-M., Wang, E., Dillehay, D.L., Rice, L.G., Meredith, F.I. and Riley, R.T. 1997. Importance of sphingolipids and inhibitors of sphingolipid metabolism as components of animal diets. *J Nutr* 127:830S-833S.
- Morgan, M.K., Schroeder, J.J., Rottinghaus, G.E., Powell, D.C., Bursian, S.J. and Aulerich, R.J. 1997. Dietary fumonisins disrupt sphingolipid metabolism in mink and increase the free sphinganine to sphingosine ratio in urine but not in hair. *Vet Hum Toxicol* 39(6):334-336.
- Motelin, G.K., Haschek, W.M., Ness, D.K., Hall, W.F., Harlin, K.S., Schaeffer, D.J. and Beasley, V.R. 1994. Temporal and dose-response features in swine fed corn screenings contaminated with fumonisin mycotoxins. *Mycopathologia* 126:27-40.
- Musser, S., Eppley, R.M. and Trucksess, M.W. 2002. Electrospray Mass Spectrometry for Fumonisin Detection and Method Validation. In: *Mycotoxins and Food Safety*, by DeVries, J.W., Trucksess, M.W. and Jackson, L.S. (Eds.). *Advances in Experimental Medicine and Biology* 504:95-105. Kluwer Academic/Plenum Publishers, New York.
- Norred, W.P., Plattner, R.D. and Chamberlain, W.J. 1993. Distribution and excretion of [¹⁴C]fumonisin B1 in male Sprague-Dawley rats. *Nat Toxins* 1:341-346.
- Norred, W.P., Voss, K.A., Riley, R.T., Meredith, F.I., Bacon, C.W. and Merrill A.H. Jr. 1998. Mycotoxins and health hazards: toxicological aspects and mechanism of action of fumonisins. *Toxicological Sciences* 23:160-164.
- Osborne, C.D., Noblet, G.P., Engongene, E.N., Bacon, C.W., Riley, R.T., Voss, K.A. 2002. Host resistance to *Trypanosoma cruzi* infection is enhanced in mice fed *Fusarium verticillioides* (= *F. moniliforme*) culture material containing fumonisins. *Food and Chemical Toxicology* 40, 1789-1798.
- Oswiler, G.D., Kehrl, M.E., Stabel, J.R., Thurston, J.R., Ross, P.F. and Wilson, T.M. 1993. Effects of fumonisin-contaminated corn screenings on growth and health of feeder calves. *J Anim Sci* 71:459-466.
- Park, J.W., Scott, P.M., Lau, B.P.-Y. and Lewis, D.A. 2004. Analysis of heat-processed corn foods for fumonisins and bound fumonisins. *Food Addit Contam* 21:1168-1178.
- Penner, J.D., Casteel, S.W., Pittman, L. Jr, Rotting G.E. and Wyatt, R.D. 1998. Developmental toxicity of purified fumonisin B1 in pregnant Syrian hamsters. *Journal of Applied Toxicology* 18:197-203.
- Pepeljnak, S., Petrinc, Z., Kovacic, S. and Segvic, M. 2003. Screening toxicity study in young carp (*Cyprinus carpio* L.) on feed amended with fumonisin B1. *Mycopathologia* 156(2):139-145.
- Petrinc, Z., Pepeljnjak, S., Kovacic, S. and Krznaric, A. 2004. Fumonisin B1 causes multiple lesions in common carp (*Cyprinus carpio*). *Dtsch Tierarztl Wochenschr*, Sep; 111(9):358-363.
- Pineiro, M.S., Silva, G.E., Scott, P.M., Lawrence, G.A. and Stack, M.E. 1997. Fumonisin level in Uruguayan corn products. *J AOAC Int* 80:825-828.
- Placinta, C.M., D'Mello, J.P.F. and MacDonald, A.M.C. 1999. A review of worldwide contamination of cereal grains and animal feed with *Fusarium* mycotoxins. *Animal Feed Science and Technology* 78:21-37.
- Powell, D.C., Bursian, S.J., Bush, C.R., Render, J.A., Rottinghaus, G.E. and Aulerich, R.J. 1996. Effects of dietary exposure to fumonisins from *Fusarium moniliforme* culture material (M-1325) on the reproductive performance of female mink. *Arch Environ Contam Toxicol* 31(2):286-292.

- Prelusky, D.B. 1994. Residues in meat, milk and eggs. In: The Toxicology Forum, Special Meeting on Mycotoxin Health Risk, Control and Regulation, February 23-24, 1994. The Capital Hilton, Washington DC, US, pp 173-185.
- Prelusky, D.B., Trenholm, H.L. and Savard, M.E. 1994. Pharmacokinetic fate of ¹⁴C labelled fumonisin B1 in swine. *Natural Toxins* 2:73-80
- Prelusky, D.B., Trenholm, H.L., Rotter, B.A., Miller, J.D., Savard, M.E., Yeug, J.M. and Scott, P.M. 1996a. Biological fate of fumonisin B1 in food producing animals. *Advances in Experimental Medicine and Biology* 392:265-278.
- Prelusky, D.B., Miller, J.D. and Trenholm, H.L. 1996b. Disposition of ¹⁴C-derived residues in tissues of pigs fed radiolabelled fumonisin B1. *Food Addit Contam* 13:155-162.
- Qureshi, M.A., Garlich, J.D., Hagler Jr., W.M. and Weinstock, D. 1995. *Fusarium proliferatum* culture material alters several production and immune performance parameters in White Leghorn chickens. *Immunopharmacology and Immunotoxicology* 17:791-804.
- Raynal, M., Bailly, J.D., Benard, G. and Guerre, P. 2001. Effects of fumonisin B1 present in *Fusarium moniliforme* culture material on drug metabolising enzyme activities in ducks. *Toxicol Lett* 121(3):179-190.
- Restum, J.C., Bursian, S.J., Millerick, M., Render, J.A., Merrill, A.H., Wang, E., Rottinghaus, G.E. and Aulerich, R.J. 1995. Chronic toxicity of fumonisins from *Fusarium moniliforme* culture material (M-1325) to mink. *Archives of Environmental Contaminants Toxicology* 29:545-550
- Rice, L.G. and Ross, P.F. 1994. Methods for detection and quantitation of fumonisins in corn, cereal products and animal excreta. *J Food Prot* 57:536-540.
- Richard, J.L., Meerdink, G., Maragos, C.M., Tumbleson, M., Bordson, G. Rice, L.G. and Ross, P.F. 1996. Absence of detectable fumonisins in the milk of cows fed *Fusarium proliferatum* (Matsushima) Nirenberg culture material. *Mycopathologia* 133:123-126.
- Riley, R.T., An, N.H., Showker, J.L., Yoo, H.S., Norred, W.P., Chamberlain, W.J., Wang, E., Merrill, A.H.Jr., Motelin, G., Beasley, V.R. and Haschek, W.M. 1993. Alteration of tissue and serum sphinganine to sphingosine ratio: an early biomarker of exposure to fumonisin-containing feeds in pigs. *Toxicology and Applied Pharmacology* 118:105-112.
- Ross, P.F., Rice, L.G., Reagor, J.C., Osweiler, G.D., Wilson, T.M., Nelson, H.A., Owens, D.L., Plattner, R.D., Harlin, K.A. and Richard, J.L. 1991. Fumonisin B1 concentrations in feeds from 45 confirmed equine leukoencephalomalacia cases. *J Vet Diagn Invest* 3:238-241.
- Riley, R.T., Hinton, D.M., Chamberlain, W.J., Bacon, C.W., Wang, E., Merrill, A.H. Jr. and Voss, K.A. 1994a. Dietary Fumonisin B1 induces disruption of sphingolipid metabolism in Sprague-Dawley rats: A new mechanism of nephrotoxicity. *Journal of Nutrition* 124:594-603.
- Riley, R.T., Voss, K.A., Yoo, H.S., Gelderblom W.C.A. and Merrill, A.H. Jr. 1994b. Mechanism of fumonisin toxicity and carcinogenesis. *Journal Food Protection* 57:638-645.
- Ross, P.F., Nelson, P.E., Owens, D.L., Rice, L.G., Nelson, H.A. and Wilson, T.M. 1994. Fumonisin B2 in cultured *Fusarium proliferatum*, M-6104, causes equine leukoencephalomalacia. *J Vet Diagn Invest* 6(2):263-5.
- Rotter, B.A., Thompson, B.K., Prelusky, D.B., Trenholm, H.L., Stewart, B., Miller, J.D. and Savard, M.E. 1996. Response of growing swine to dietary exposure to pure fumonisin B1 during an eight-week period: growth and clinical parameters. *Nat Toxins* 4(1):42-50.

- Schroeder, J.J., Crane, H.M., Xia, J., Liotta, D.C. and Merrill, A.H.Jr. 1994. Disruption of sphingolipid metabolism and stimulation of DNA synthesis by fumonisin B₁. A molecular mechanism for carcinogenesis associated with *Fusarium moniliforme*. *J Biol Chem* 269(5):3475-81.
- Scudamore, K.A., Hetmanski, M.T., Chan, H.K., and Collins, S. 1997. Occurrence of mycotoxins in raw ingredients used for animal feeding stuffs in the United Kingdom in 1992. *Food Additives and Contaminants* 14:157-173.
- Scudamore, K.A., Nawaz, S. and Hetmanski, M.T. 1998. Mycotoxins in ingredients of animal feeding stuffs: II. determination of mycotoxins in maize and maize products. *Food Additives and Contaminants* 15:30-55.
- Seefelder, W., Hartl, M. and Humpf, H.-U. 2001. Determination of N-(Carboxymethyl)fumonisin B₁ in Corn Products by Liquid Chromatography/Electrospray Ionization-Mass Spectrometry. *J Agric Food Chem* 49:2146-2151.
- Seefelder, W., Knecht, A. and Humpf, H.-U. 2003. Bound Fumonisin B₁: Analysis of Fumonisin-B₁ Glyco and Amino Acid Conjugates by Liquid Chromatography-Electrospray Ionization-Tandem Mass Spectrometry. *J Agric Food Chem* 51:5567-5573.
- Sharma, R.P., Gugyala, R.R. and Voss, K.A. 1997. Demonstration of in-situ apoptosis in mouse liver and kidney after short term repeated exposure to fumonisins B₁. *Journal of Comparative Pathology* 177:371-381.
- Shephard, G.S. 1998. Chromatographic determination of fumonisin mycotoxins. *J Chromatography A* 815:31-39.
- Shephard, G.S. and Sewram, V. 2004. Determination of the mycotoxin fumonisin B₁ in maize by reversed-phase thin-layer chromatography: a collaborative study. *Food Additives and Contaminants* 21:498-505.
- Shetty, P.H. and Bhat, R.V. 1997. Natural occurrence of fumonisin B₁ and its co-occurrence with aflatoxin B₁ in Indian sorghum, maize and poultry feeds. *J Agric Food Chem* 45:2170-2173.
- Smith, J.S. and Thakur, R.A. 1996. Occurrence and fate of fumonisins in beef. *Advances in Experimental Medicine and Biology* 392:39-55.
- Smith, G.W., Constable, P.D. and Hascheck, W.M. 1996. Cardiovascular responses to short-term fumonisin exposure in swine. *Fundamental and Applied toxicology* 33:140-148.
- Smith, G.W., Constable, P.D., Tumbleson, M.E., Rottinghaus, G.E. and Haschek W.M. 1999. Sequence of cardiovascular changes leading to pulmonary edema in swine fed culture material containing fumonisin. *American Journal of Veterinary Research* 60:1292-1300.
- Smith, G.W., Constable P.D., Foreman, J.H., Eppley, R.M., Waggoner, A.L., Tumbleson, M.E. and Waschek, W.M. 2002. Cardiovascular changes associated with intravenous administration of fumonisin B₁ in horses. *American Journal of Veterinary Research* 63(4):538-545
- Spotti, M., Maas, R.F., de Nijs, C.M. and Fink-Gremmels, J. 2000. Effect of fumonisin B(1) on rat hepatic P450 system. *Environmental Toxicology and Pharmacology* 8(3):197-204.
- Spotti, M., Caloni, F., Fracchiolla, L., Pompa, G., Vigo, D. and Maffeo, G. 2001. Fumonisin B₁ carry-over into milk in the isolated perfused bovine udder. *Vet Human Toxicol* 43:109-111.
- Tolleson, W.H., Couch, L.H., Melchior, W.B.Jr., Jenkins, G.R., Muskhelishvili, M., Muskhelishvili, L., McGarrity, L.J., Domon, O., Morris, S.M. and Howard, P.C. 1999.

- Fumonisin B1 induces apoptosis in cultured human keratinocytes through sphinganine accumulation and ceramide depletion. *Int J Oncol* 14(5):833-43.
- Tran, S.T., Bailly, J.D., Tardieu, D., Durand, S., Benard, G, Guerre, P. 2003. Sphinganine to sphingosine ratio and predictive biochemical markers of fumonisin B1 exposure in ducks. *Chemico-Biological Interactions* 146(1):61-72.
- Tran, S.T., Auvergne, A., Benard, G., Bailly, J.D., Tardieu, D., Babile, R. and Guerre, P. 2005. Chronic effects of fumonisin B1 on ducks. *Poult Sci* 84(1):22-28.
- Trucksess, M.W. 2003. General Referee Reports. Committee on Natural Toxins and Food Allergens. *J AOAC International* 86:129-138.
- Tryphonas, H., Bondy, G., Miller, J.D., Lacroix, F., Hodgen, M., Mcguire, P., Fernie, S., Miller, D. and Hayward, S. 1997. Effects of fumonisin B1 on the immune system of Sprague-Dawley rats following a 14 day oral (gavage) exposure. *Fundamental and applied Toxicology* 39:53-59.
- Tuan, N.A., Manning, B.B., Lovell, R.T. and Rottinghaus, G.E. 2003. Responses of Nile tilapia (*Oreochromis niloticus*) fed diets containing different concentrations of moniliformin or fumonisin B-1. *Aquaculture* 217(1-4):515-528.
- US-FDA (United States Food and Drug Administration), 2001. Guidance for Industry: Fumonisin Levels in Human Foods and Animal Feeds, November 9, 2001.
- US-NTP (United States National Toxicology Program), 1999. Toxicology and carcinogenesis studies of fumonisin B₁ (CAS no 116355-83-0) in F344/N Rats and B6C3F Mice (Feed studies). NTP Technical Report TR 496; NIH Publication No 99-3955. U.S. Department of Health and Human Services, Research Triangle Park, North Carolina, USA.
- Van der Westhuizen, L., Shephard, G.S. and van Schalkwyk, D.J. 2001. The effect of repeated gavage doses of fumonisin B1 on the sphinganine and sphingosine levels in vervet monkeys. *Toxicol* 39(7):969-72.
- Voss, K.A., Chamberlain, W.J., Bacon, C.W., Herbert, R.A., Walters, D.B. and Norred, W.P. 1995. Subchronic feeding study of the mycotoxin fumonisin B1 in B6C3F1 mice and Fischer 344 rats. *Fundam Appl Toxicol* 24(1):102-10.
- Wang, E., Ross, P.F., Wilson, T.M., Riley, R.T. and Merrill, A.H.Jr. 1992. Increases in serum sphingosine and sphinganine and decreases in complex sphingolipids in ponies given feed containing fumonisins, mycotoxins produced by *Fusarium moniliforme*. *The Journal of Nutrition* 122:1706-1716.
- Wang, E., Riley, R.T., Meredith, F.I. and Merrill, A.H.Jr. 1999. Fumonisin B1 consumption by rats causes reversible, dose-dependent increases in urinary sphinganine and sphingosine. *Journal of Nutrition* 129:214-220.
- Weibking, T.S., Ledoux, D.R., Bermudez, A.J., Turk, J.R., Rottinghaus, G.E., Wang, E. and Merrill, A.H.Jr. 1993. Effects of feeding *Fusarium moniliforme* culture material, containing known levels of fumonisin B1, on the young broiler chick. *Poult Sci* 72:456-466.
- Weibking, T., Ledoux, D.R., Bermudez, A.J., Turk, J.R. and Rottinghaus, G.E. 1995. Effects on turkey poults of feeding *fusarium-moniliforme* m-1325 culture material grown under different environmental-conditions. *Avian Dis* 39(1):32-38.
- WHO-IPCS (World Health Organization - International Programme on Chemical Safety), 2000. Fumonisin B1. Environmental Health Criteria 219. World Health Organization, Geneva. <http://www.inchem.org/documents/ehc/ehc/ehc219.htm>.

- Wilson, T.S., Ross, P.F., Owens, D.L., Rice, L.G., Green, S.A., Jenkins, S.J. and Nelson, H.A. 1992. Experimental reproduction of ELEM- a study to determine the minimum toxic dose in ponies. *Mycopathologia* 117:115-120
- Wisniewska-Dmytrow, H., Kozak, A and Zmudzki, J. 2004. Occurrence of Fusarium mycotoxins in feedstuffs from farms with husbandry problems. *Bulletin of the Veterinary Institute in Pulawy* 48:117-122.
- Yoo, H.-S., Norred, W.P., Wang, E., Merrill, A.H.Jr. and Riley, R.T. 1992. Fumonisin inhibition of *de novo* sphingolipid biosynthesis and cytotoxicity are correlated in LLC-PK₁ cells. *Toxicology and Applied Pharmacology* 114:9-15.
- Zomborszky-Kovács, M., Kovács, F., Vetési, F., Repa, I., Tornyo, G. and Toth, A. 2002a. Investigations into the time- and dose-dependent effect of fumonisin B-1 in order to determine tolerable limit values in pigs. *Livestock Production Science* 76(3):251-256.
- Zomborszky-Kovács, M., Vetési, F., Horn, P., Repa, I. and Kovács, F. 2002b. Effects of prolonged exposure to low dose Fumonisin B1 in pigs. *Journal of Veterinary Medicine series B* 49(4):197.

SCIENTIFIC PANEL MEMBERS

Jan Alexander, Herman Autrup, Denis Bard, Angelo Carere, Lucio Guido Costa; Jean-Pierre Cravedi, Alessandro Di Domenico, Roberto Fanelli, Johanna Fink-Gremmels, John Gilbert, Philippe Grandjean, Niklas Johansson, Agneta Oskarsson, Andrew Renwick, Jirí Ruprich, Josef Schlatter, Greet Schoeters, Dieter Schrenk, Rolaf van Leeuwen, Philippe Verger.

ACKNOWLEDGEMENT

The Scientific Panel on Contaminants in the Food Chain wishes to thank Sven Dänicke, Hans van Egmond, Johanna Fink-Gremmels, John Gilbert, Jürgen Gropp, John Christian Larsen, Hans Pettersson and Ron Walker for the contributions to the draft opinion.